NOTV

Inotiv, Inc. Stock Price

NasdaqCM:NOTV Community·US$49.8m Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

NOTV Share Price Performance

US$1.39
-0.45 (-24.46%)
74.7% undervalued intrinsic discount
US$5.50
Fair Value
US$1.39
-0.45 (-24.46%)
74.7% undervalued intrinsic discount
US$5.50
Fair Value
Price US$1.39
AnalystConsensusTarget US$5.50
AnalystLowTarget US$2.50

NOTV Community Narratives

AnalystConsensusTarget·
Fair Value US$5.5 72.4% undervalued intrinsic discount

Global Pharma And Biotech R&D Increase Will Build Value

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AnalystLowTarget·
Fair Value US$2.5 39.2% undervalued intrinsic discount

Debt And Shifting Regulations Will Strain Performance But Prompt Recovery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent NOTV News & Updates

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump

Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump

May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump

Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?

Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?

Inotiv, Inc. Key Details

US$505.3m

Revenue

US$387.4m

Cost of Revenue

US$117.9m

Gross Profit

US$196.9m

Other Expenses

-US$79.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-2.30
Gross Margin
23.33%
Net Profit Margin
-15.63%
Debt/Equity Ratio
275.8%

Inotiv, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with slight risk.

4 Risks
2 Rewards

About NOTV

Founded
1974
Employees
2026
CEO
Robert Leasure
WebsiteView website
www.inotiv.com

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.8%
  • 3 Months: 5.3%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
The market has been flat over the last week. As for the longer term, the market has risen 17% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›